Citations 4
Two-year durability of REBYOTA™ (RBL), a live biotherapeutic for the prevention of recurrent Clostridioides difficile infections
Orenstein, Robert , Hecht, Gail , Tillotson, Glenn S. , Khanna, Sahil , Harvey, Adam
Open Forum Infectious Diseases | September 8, 2023 | Volume: 10 | Issue: 9 | Pages: No page available
1950. Prevention of Recurrent Clostridium difficile at Six Months Following Treatment With Microbiota-Based Therapy RBX2660: Durability Results From a Phase 2 Open-Label Study
Mische, Sarah, Orenstein, Robert , Khanna, Sahil , Hecht, Gail , Lee, Christine , Dubberke, Erik R. , DuPont, Herbert L. , Blount, Ken
Open Forum Infectious Diseases | November 26, 2018 | Volume: 5 | Issue: suppl_1 | Pages: S562-S563
Results From a Randomized, Placebo-Controlled Clinical Trial of a RBX2660—A Microbiota-Based Drug for the Prevention of Recurrent Clostridium difficile Infection
Lee, Christine H. , Orenstein, Robert , Khanna, Sahil , Hecht, Gail , Gerding, Dale N. , Dubberke, Erik R.
Clinical Infectious Diseases | March 28, 2018 | Volume: 67 | Issue: 8 | Pages: 1198-1204
Efficacy and Safety of RBX2660 for the Prevention of Recurrent Clostridium difficile Infection: Results. of the PUNCH CD 2 Trial
Lee, Christine , Orenstein, Robert , Khanna, Sahil , Hecht, Gail , Fraiz, Joseph, Dubberke, Erik R. , Lee, Christine H.
Open Forum Infectious Diseases | February 1, 2017 | Volume: 3 | Issue: suppl_1 | Pages: No page available